INTRODUCTION
The combination of cytarabine and anthracycline induces complete remission (CR) in up to 80% of adults with acute myeloid leukemia (AML). 1 This rate decreases with older age and the presence of unfavorable cytogenetic and/or molecular genetic abnormalities.
2, 3 Relapse risk in first CR (CR1) and the probability of survival are mainly determined by disease-specific risk factors. The cytogenetic risk profile of AML blasts is an established prognostic feature, 4 and for AML with an unfavorable karyotype, allogeneic stem-cell transplantation (alloSCT) is accepted as being the preferred postremission therapy (PRT). 5, 6 In terms of relapse risk, alloSCT is the most effective antileukemic treatment option. However, this approach bears concerns with regard to increased nonrelapse mortality and high morbidity rates, mostly associated with graft-versus-host disease (GVHD).
comparisons, however, can be confounded by patients with no siblings and those even not HLA typed but grouped as no donor, thus introducing a substantial bias. 13 In addition, donor versus no-donor trials do not take into account that a substantial proportion of patients receive alloSCT from unrelated donors, after similar survival results were found in patients with AML who received transplants from well-matched unrelated donors as from HLA identical siblings.
14 In the present study, we therefore compared both PRT options, alloSCT from matched related or unrelated donors with conventional PRT, within a prospectively matched pairs patient cohort of the AMLCG99 trial. By inclusion of patients who received transplants from unrelated donors, matching very closely for the major prognostic factors and by calendar time, our novel study design of a prospective comparison of different PRTs for patients with AML in CR1 avoids most of the potential selection biases as found in donor versus no-donor comparisons.
PATIENTS AND METHODS

Treatment Plan
Details of the AMLCG99 study have been previously reported. 15, 16 In short, patients Ն 16 years of age with newly diagnosed AML, or patients with myelodysplastic syndrome (MDS) with more than 10% bone marrow CONSORT diagram outlining the flow of patients within the AMLCG99 trial. alloSCT, allogeneic stem-cell transplantation; AML IG, AML intergroup trial; conblasts, were randomly assigned upfront to receive (1) a double induction of standard-dose cytarabine-containing TAD (thioguanine, cytarabine, and daunorubicin) followed by high-dose cytarabine-containing HAM (high-dose cytarabine, mitoxantrone) versus HAM-HAM, (2) priming with granulocyte colony-stimulating factor starting 48 hours before chemotherapy versus no priming, and (3) PRT with TAD consolidation followed by autologous stemcell transplantation versus TAD followed by prolonged maintenance chemotherapy. Patients younger than 60 years of age at diagnosis with intermediate cytogenetic risk and an HLA-identical sibling and patients younger than 60 years of age with adverse cytogenetic risk and either an HLA-identical sibling or an unrelated donor were offered an alloSCT instead of the assigned PRT. Conditioning regimens, GVHD prophylaxis, and supportive care were performed according to the transplantation center's standard. Cytogenetic risk classification has been previously reported.
15,16
Matching Procedure
Prospectively defined by the protocol, each patient receiving an alloSCT as consolidation in first CR was matched to a similar partner who was treated with conventional PRT. Evaluation of treatment response to induction treatment was scheduled by protocol after hematologic recovery after the second induction therapy. Main matching criteria were stratified cytogenetic risk (favorable with t(8;21); favorable without t(8;21); intermediate, normal karyotype; intermediate, aberrant karyotype; unfavorable, noncomplex; and unfavorable, complex karyotype with at least three aberrations not including good-risk aberrations), age at diagnosis Ϯ 5 years (because treatment intensity of patients Ն 60 years of age differed considerably compared with younger patients, 15 only patients younger than 60 were eligible for the conventional postremission group), remission duration (remission of an eligible conventional PRT patient had to be at least as long as the time between CR and alloSCT of the partner who underwent transplantation), and type of AML, stratified into de novo; secondary evolving from previous myelodysplastic syndrome (sAML); therapy-related AML after cytotoxic treatment (chemotherapy or irradiation, t-AML); or high-risk MDS. All major matching criteria had to be fulfilled for a patient to be eligible as conventional PRT partner. Minor criteria were sex, randomization to induction therapy, and CR date. Those criteria were considered for the matching procedure only if more than one eligible conventional PRT partner existed. Matching was performed as soon as the transplantation procedure was documented and performed centrally in the Institute of Biostatistics and Clinical Research of the University of Muenster.
Statistics
All analyses were performed on SPSS version 21 (SPSS, Chicago, IL) and XLSTAT version 2012.5.01 (Addinsoft, Paris, France). Categorical variables were compared by 2 test and continuous variables by Mann-Whitney U test of independent cohorts. Overall survival from CR (OS) was defined by the time between CR achievement after induction therapy until death from any cause, and relapse-free survival (RFS) as time between CR achievement and relapse or death, whatever occurred first. Patients without an event were censored at the time of their last follow-up. Cumulative incidence of relapse and nonrelapse-related mortality (NRM) were calculated using cumulative incidence estimates to accommodate competing risks (mortality in this analysis refers to number of deaths per number of patients involved in this evaluation). For analysis of NRM, an event was defined as death while in CR. NRM events for the PRT group were death in CR1. Deaths from any causes after alloSCT performed after relapse were not calculated as NRM events. Survival times were estimated by Kaplan-Meier method and compared by log-rank test. Cumulative incidence of relapse and NRM were compared by Gray test. Hazard ratios for OS and RFS were determined by Cox regression analysis. An additional Cox regression analyses was performed for OS and RFS stratified by patient pairs. For determination of risk factors, a multivariable Cox regression analysis was performed including the identified risk factors as well as treatment group (alloSCT v conventional PRT) with backward selection. Selection criteria were ␣ ϭ 0.05 for inclusion and ␣ ϭ 0. 
RESULTS
Patient Characteristics
Between 1999 and 2011, 3,540 patients entered the AMLCG99 trial. In first CR, 224 patients Յ 59 years of age at diagnosis received an alloSCT for consolidation treatment. For the flow of patients through this trial, see CONSORT statement (Fig 1) . For 185 patients, a matched conventional PRT partner could be identified. In the conventional PRT group, 82 patients were upfront assigned to autologous SCT. Seven patients of our study population actually received an autologous transplantation. Autologous transplantation was replaced by maintenance chemotherapy in most of the cases mainly because of insufficient stem-cell mobilization or by physician's decision, after a previous report showed equivalence of maintenance chemotherapy and autologous transplantation.
16 Table 1 shows the baseline characteristics of matched patients. According to matching criteria, patients were equally distributed regarding age, cytogenetic risk classification, and diagnosis. In addition, no differences were detectable regarding sex, French-American-British type, leukocytes at diagnosis (WBC), LDH, or randomization of induction treatment. There were no significant differences in incidence of the favorable genetic combination NPM mutated/no FLT3-ITD between the alloSCT and conventional PRT group. Median time between start of induction treatment and achievement of CR was 62 days in the alloSCT group and 68 days in the conventional PRT group, again with no significant differences.
Transplantation in the alloSCT group was performed at a median of 82 days after CR1 was achieved (Table 1 ) from matched related donor (MRD, n ϭ 115), matched unrelated donor (MUD, n ϭ 46), mismatched related donor (MMRD, n ϭ 2) and mismatched unrelated donor (MMUD, n ϭ 22), and after standard intensity conditioning (SIC) in 106 patients, preferentially in younger ones (median age, 44 years; range, 16 to 58 years), and dose-reduced/dose-adapted conditioning (RIC) in 79 patients (median age, 47 years; range, 16 to 59 years). Ninety-eight patients received at least one consolidation therapy with TAD according to the protocol, and 87 patients underwent transplantation after induction therapy without further conventional consolidation chemotherapy. With regard to RFS and OS, application of further conventional consolidation chemotherapy before alloSCT did not have any impact on survival. Sixty-eight patients (57% of patients with AML relapse) in the conventional PRT group received an alloSCT after relapse from an MRD (n ϭ 24) or MUD/MMUD (n ϭ 44), with SIC (n ϭ 32) or RIC (n ϭ 36). The OS rate of these patients who received transplants from an allogeneic donor after relapse was 36% (95% CI, 24% to 48%) at 7 years after documented CR1.
Thirty-nine patients received an alloSCT in first CR but could not be matched because no comparable counterpart in the conventional PRT group could be identified. These patients had a higher cytogenetic risk, a lower incidence of de novo AML, lower WBC, and a shorter interval between CR achievement and transplantation (Appendix Table A1, online only). OS and RFS at 7 years of these patients was 49% (95% CI, 31% to 66%) and 49% (95% CI, 32% to 67%), respectively (Appendix Fig A2, online only) . Nine patients with favorable cytogenetic risk received an alloSCT as consolidation treatment while in first CR. Persistence of minimal residual disease (measured by cytogenetic or molecular genetic methods) was the major reason to perform an alloSCT in first CR in favorable cytogenetic risk patients.
Outcome
Median follow-up after documentation of CR was 7.9 years. Projected 7-year OS after CR was better in the alloSCT group, with 58% (95% CI, 51% to 65%) versus 46% (95% CI, 39% to 54%) in the conventional PRT group (P ϭ .037; Fig 2A) . An analysis stratified by patient pairs revealed a trend for improved survival (P ϭ .188) and a significant (P Ͻ .001) benefit for RFS in the alloSCT group versus the conventional PRT group. NRM after 7 years was higher in the alloSCT group (24%; 95% CI, 18% to 32%) versus the conventional PRT group (6%; 95% CI, 2% to 13%; P Ͻ .001; Fig 2B) . Matched alloSCT patients had a projected RFS after 7 years of 52% (95% CI, 45% to 60%) compared with 34% (95% CI, 26% to 41%; P Ͻ .001) for their RFS and CI relapse P < .001
Fig 2. Kaplan-Meier survival estimates and cumulative incidences of nonrelapse mortality (NRM) and relapse according to postremission therapy. Data are shown for (A) overall survival (OS) and cumulative incidences of NRM and (B) relapse-free survival (RFS) and cumulative incidences (CI) of relapse. Gold lines depict cumulative incidences, blue lines survival curves. Tick marks represent (A) patients whose data were censored at the last time they were known to be alive or (B) whose data were censored at the last time they were known to be alive and in complete remission. NRM events for the postremission therapy (PRT) group were deaths in CR1 (first complete remission). alloSCT, allogeneic stem-cell transplantation; convent. PRT, conventional PRT.
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www.jco.org conventional postremission chemotherapy counterparts (Fig 2B) . The cumulative incidence of AML relapse after 7 years was 36% (95% CI, 28% to 42%) in the alloSCT cohort versus 65% (95% CI, 58% to 72%; P Ͻ .001) in the conventional PRT cohort (Fig 2B) .
Multivariable analysis of risk factors revealed that alloSCT was an independently associated with superior OS (hazard ratio, 0.66; 95% CI, 0.49 to 0.89). In addition, adverse risk factors were older age, unfavorable cytogenetics, and persisting bone marrow blasts (Ն 10%) after the first induction cycle.
Subgroups
Subgroup analyses showed an improved OS after alloSCT in the 75 patient pairs with nonfavorable chromosomal aberrations (Figs 3A and 5A), in the pairs with an age of the alloSCT partner above the median of 45 years (Figs 4A and 5A), in patients without de novo AML (sAML, t-AML or high-risk MDS), and in patients with blast clearance in the early bone marrow assessment on day 16 after initiation of therapy (Fig 5A) . RFS was better in the alloSCT group in patients with intermediate and adverse cytogenetic risk (Figs 3B and 5B), within the intermediate-risk group in patients with cytogenetic aberrations (Fig 5B) , in patient pairs with the age of the alloSCT partner above the median age (Figs 4B and 5B), and in patients with blast clearance after one induction cycle. AlloSCT showed increased RFS irrespective of sex, LDH level at diagnosis, and type of disease (Fig 5B) . NRM was higher in the alloSCT cohort in patients with intermediate Intermediate karyotype (n = 270, P < .001) Unfavorable karyotype (n = 82, P < .001) Tick marks represent (A) patients whose data were censored at the last time they were known to be alive or (B) whose data were censored at the last time they were known to be alive and in CR. Curves for the favorable karyotype subgroups overlap (A and B). cytogenetic risk and irrespective of age (Figs 3C and 4C), and cumulative incidence of relapse was lower in the alloSCT cohort in patients with intermediate and unfavorable karyotype and throughout both age groups (Figs 3D and 4D ).
DISCUSSION
We here report results of a large multicenter study in which patients undergoing alloSCT in first CR were pairwise compared with matched partners receiving conventional postinduction treatment in a prospective fashion. We show that alloSCT is the most potent PRT for AML with unfavorable and intermediate-risk karyotype. In addition, and in contrast to other studies, 10,12 our analysis suggests that age more than 45 years might be a predictive factor, which favors alloSCT in first CR.
Over the last years, most reported studies used a Mendelian or genetic allocation for the assessment of alloSCT in comparison with conventional therapy. In this particular context, whether or not a patient has a matched sibling donor was used as a surrogate for randomization. Although such an approach, with some restrictions, might be useful in limiting a selection bias, it has the disadvantage in underestimating the effects of alloSCT as a PRT, as a relevant number of patients with a sibling donor receive the transplant in later stages of disease, and a fraction of patients in the "no donor" group might receive an alloSCT from an unrelated donor.
19,20 With comparable results after alloSCT, using wellmatched unrelated donors or sibling donors, declining treatmentassociated morbidity and mortality rates with improvements in HLA matching, antimicrobial therapy, and prophylaxis and management of GVHD, alloSCT has become an increasingly applicable treatment option for more patients with AML.
14,21,22
To better define the role of alloSCT in comparison with conventional chemotherapy for postremission management, the AMLCG99 trial included a predefined analysis of patients receiving allogeneic transplants from related or unrelated donors, matched to patients treated with conventional chemotherapy after achieving CR1. One of the major strengths of our study was that the matching was done per protocol and prospectively. Therefore, the matching is more or less contemporaneous, thereby controlling carefully for calendar time, which is correlated with improvements in prophylaxis and supportive care and possibly also with the likelihood of receiving a transplant. One restriction of our study is that not all patients in CR could be considered; for 39 patients who underwent transplantation in CR1 with preferentially unfavorable cytogenetic risk or no de novo AML, no matching partner could be identified. In addition, 545 patients in CR with conventional postremission treatment were not matched to a partner receiving alloSCT in CR1. An analysis of all 954 CR patients younger than 60 years according to postremission treatment was biased by early events within the first 6 months after CR achievement, before an alloSCT could have taken place (Appendix Fig A3, online only) . In consequence of the imbalance of patients with high-risk AML in both treatment groups and early events after CR, mainly occurring in patients receiving conventional postremission treatment, such an analysis of all CR patients is insufficient to determine the impact of different postremission treatment strategies.
At In addition to cytogenetic risk, several molecular markers have recently been discovered to bear prognostic influence for patients with cytogenetically normal AML. Among them are the internal tandem duplications of the fms-related tyrosine kinase 3 gene (FLT3-ITD) as adverse, 24 and mutations in the nucleophosmin gene 1 (NPM1) gene 25, 26 and (biallelic) mutations in the CCAAT enhancer binding protein ␣ (CEBPA) 27,28 as favorable prognostic factors. Although the prognostic influence of other recently discovered gene mutations is less clear, mutations of those genes have already been incorporated in current AML prognostification systems. 23 However, their predictive value with regard to alloSCT versus conventional PRT remains a matter of debate. For example, the donor versus no donor comparison, reported by Schlenk et al, 11 suggests a benefit for alloSCT in patients with AML with normal karyotype and with a molecular risk now classified as intermediate I according to the ELN classification (FLT3-ITD, or no FLT3-ITD and wild type for both genes NPM1 and CEBPA). In contrast, other data found a beneficial effect of alloSCT with regard to RFS in patients with NPM1 mutations.
29
Because those gene mutations were not known at the time of initiation of the AMLCG 1999 study, they could not be included into the prospectively defined matching criteria of current analysis. Considering the almost identical hazard ratios of patients with mutated NPM and no FLT3-ITD compared with other NPM1/FLT3 combinations (Fig 5 and Appendix Fig A1, online only) , the impact of alloSCT in patients with AML with normal karyotype occurs independent of these gene mutations in our analysis.
Interestingly, and in stark contrast to other studies, 10,12 our data suggest that particularly patients between 46 and 59 years of age may benefit from alloSCT in CR1. This could be explained in part by the introduction of dose-adapted conditioning regimens with acceptable toxicities even in older patients, 22 improvement in supportive care and, conversely, better transplant results after relapse, especially in younger patients. Moreover, patients 18 to 45 years of age who underwent transplantation in CR1 and matched control patients receiving conventional PRT showed similar survival rates. One explanation for this observation might be that many patients, particularly the intermediate karyotype subgroup, can be rescued by an alloSCT after AML relapse.
9,19
In summary, the findings from this prospective matched pairs analysis demonstrate that alloSCT is the most potent PRT for patients with AML in CR1. In contrast to previously published data, our results indicated that the positive impact of this treatment modality with regard to OS is especially evident in patients with abnormal karyotype not classified as favorable, including patients with intermediate risk and patients between 46 and 59 years of age. Survival curve for (A) overall survival and (B) relapse-free survival in blue with 95% CIs (gold lines). Tick marks represent (A) patients whose data were censored at the last time they were known to be alive or (B) whose data were censored at the last time they were known to be alive and in complete remission (relapse-free survival). For detailed patients characteristics, see Appendix Table A1 . ) relapse-free survival (RFS) of 954 patients younger than 60 years achieving a first complete remission (CR1) treated within the AMLCG99 trial. Tick marks represent (A) patients whose data were censored at the last time they were known to be alive or (B) whose data were censored at the last time they were known to be alive and in complete remission. Of 162 relapses or death in CR1 (RFS events) occurring within 180 days after CR achievement in patient group receiving a conventional postremission therapy (convent. PRT), 140 were relapses and, of these, 75 patients underwent allogeneic stem-cell transplantation (alloSCT).
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